C1 Inhibitor Antigen (C1-INH Antigen)
Major circulating serine protease inhibitor (serpin) that irreversibly inactivates C1r, C1s, MASP-1/2, Factor XIIa, and plasma kallikrein.
Standard vs. Optimal Reference Rangesmg/dL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
19 - 37 mg/dL
General reference distribution across unselected commercial populations.
22 - 34 mg/dL
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Inhibits plasma kallikrein-mediated generation of bradykinin from high-molecular-weight kininogen (HMWK).
Differential Diagnosis
Elevated Levels (C1-INH Antigen High)
- •Normal serpin regulation of kallikrein and complement
Low Levels (C1-INH Antigen Low)
- •Type I Hereditary Angioedema (HAE-1, quantitative deficiency)
- •Acquired C1-INH deficiency (lymphoproliferative disorders)
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for C1-INH Antigen
- Targeted organ system imaging or functional dynamic testing related to hereditary angioedema type i
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of C1 Inhibitor Antigen - The New England Journal of Medicine (2021). PMID: 34190124
- [2]C1-INH Antigen Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35422901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate C1 Inhibitor Antigen (C1-INH Antigen) into overall healthspan optimization.